Response definition criteria for ELISPOT assays revisitedZoe Moodie, Cedrik M. Britten, Leah Price et al.|Cancer Immunology Immunotherapy|2010Cited by 231
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell ResponseMariëtte I.E. van Poelgeest, Sjoerd H. van der Burg, Harry Hollema et al.|Clinical Cancer Research|2016Cited by 166
Guidelines for the automated evaluation of Elispot assaysSylvia Janetzki, Axel Hoos, Leah Price et al.|Nature Protocols|2015Cited by 88
HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasiaSanne Samuels, Gemma G. Kenter, A. Marijne Heeren et al.|Cancer Immunology Immunotherapy|2017Cited by 19
Supplementary Materials from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell ResponseMariëtte I.E. van Poelgeest, Sjoerd H. van der Burg, Marij J.P. Welters et al.|Unknown|2023Cited by 0